<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01112410</url>
  </required_header>
  <id_info>
    <org_study_id>09023JB-OPMS</org_study_id>
    <nct_id>NCT01112410</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis</brief_title>
  <official_title>A Randomised Double Blind 13 Week Crossover Trial of Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Patients With Bronchiectasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belfast Health and Social Care Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesise that nebulised hypertonic saline (6%) will increase the volume
      of sputum expectorated over a 24 hour period compared to nebulised isotonic saline (0.9%) in
      patients with mild to severe stable bronchiectasis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour sputum volume</measure>
    <time_frame>13 weeks</time_frame>
    <description>24 hour volume sputum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Testing</measure>
    <time_frame>13 weeks</time_frame>
    <description>Spirometry (FEV1 and FVC) will assess the side effects using HTS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rheology</measure>
    <time_frame>13 weeks</time_frame>
    <description>Rheology is the measurement of the viscosity and elasticity of sputum (viscoelasticity) and also the thread forming ability of mucus (spinnibility). Rheology will assess the extent to which HTS effect the viscosity of secretions and rehydrates secretions by drawing water into the mucus via osmosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>13 weeks</time_frame>
    <description>All used and unused vials of the study drug shall be counted. The researcher will review the returned vials (used and unused) along with the patient diary cards, which record information regarding airway clearance and administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes RSSQ</measure>
    <time_frame>13 weeks</time_frame>
    <description>RSSQ: a signs and symptoms questionnaire used in clinical trials in order to diagnose an exacerbation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome: Leicester Cough Questionnaire:</measure>
    <time_frame>13 weeks</time_frame>
    <description>Leicester Cough Questionnaire: a valid and reliable health status measure for adults with chronic cough
Quality of Life Questionnaire Bronchiectasis (QOL-B), a tool used to evaluate quality of life in patients with bronchiectasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchiectasis Qol Questionnaire</measure>
    <time_frame>13 weeks</time_frame>
    <description>Bronchiectasis Qol Questionnaire is a disease specific questionnaire developed to assess disease specific QOL in Bronchiectasis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bronchiectasis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>Hypertonic saline (6%) nebulised twice a day for 4 weeks.
(Randomised crossover trial)</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non CF Bronchiectasis

          -  18-80 years

          -  FEV1 less than 90%

          -  Chronic sputum production

          -  Clinical stable

        Exclusion Criteria:

          -  Intolerance to HTS

          -  Use of HTSaline or antibiotics 14 days prior to study

          -  Clinically unstable

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Belfast HSCT</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Bradley, PHD</last_name>
      <phone>+44 28 90329241</phone>
      <phone_ext>2719</phone_ext>
      <email>jm.bradley@ulster.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2010</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Judy Bradley</name_title>
    <organization>Belfast Health and Social Care Trust</organization>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>Hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

